UNASSIGNED: 7227 Background: Positron emission tomography (PET) is more accurate than computed tomography (CT) in the staging of @entity1149 ( @entity1149 ). We analyzed the prognostic value of PET for survival in @entity1149 @entity1 . METHODS: Consecutive @entity1 with proven @entity1149 who had PET for staging were selected. All @entity1 had been evaluated by laboratory tests, bronchoscopy, chest X- @entity16039 , and CT of the chest and upper abdomen. A clinical stage (c- @entity2802 ) was determined prior to PET. A pet- @entity2802 was obtained by observers blinded to clinical data. We used the McNemar test to compare c- @entity2802 and pet- @entity2802 . Univariate survival analyses were performed with the Kaplan-Meier method and log rank test, for performance score, sex, @entity353 , comorbidity, histology, hilar and paramediastinal @entity5 location, c- @entity2802 , and pet- @entity2802 . Cox regression analysis was performed with the significant variables of the univariate analyses, together with age and interaction variables. RESULTS: From 1996 until 2001, 268 @entity1 were included, 206 @entity1 and 62 @entity1 . Median age was 63 years (range, 29-88), ECOG performance score was 0/1/2 in 114/135/19 @entity1 , 37% had squamous and 30% had @entity420 . c- @entity2802 and pet- @entity2802 were identical in 150 (56%) @entity1 , 68 were upstaged and 48 were downstaged by PET, and 2 without c- @entity2802 had stage IB/IV. c- @entity2802 did not overlap with pet- @entity2802 (p = 0.024). At analysis, 212 (79%) @entity1 had died. Median survival in months was not reached for stage IA (pet- @entity2802 ), 45 for stage IB, 21 for IIA, 29 for IIB, 13 for IIIA, 14 for IIIB, and 9 for stage IV. At univariate analysis, survival difference between the arms was significant for performance score (0 vs. 1/2), @entity353 (< 10% vs. >=  10%), @entity358 and paramediastinal location (no vs. yes), c- @entity2802 and pet- @entity2802 (stage I vs. II vs. IIIA vs. IIIB vs. IV). At Cox regression analysis, pet- @entity2802 was the only significant (p < 0.001) predictor of poor survival, while c- @entity2802 , performance score, and @entity353 were not significant. CONCLUSION: @entity5 stage as determined by PET is the best prognostic factor for survival in @entity1 with @entity1149 . No significant financial relationships to disclose.

Prognostic value of positron emission tomography for XXXX survival; analysis of 268 cases.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity16039 :: ('255564', 'Species') :: ['ray'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity2802 :: ('10178', 'Gene') :: ['TNM'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary comorbidity'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
